Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-10-27
1999-07-27
McKane, Joseph K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514411, 514416, 514381, 548251, 548430, 548454, 548470, A61K 31405, C07D20910
Patent
active
059291060
ABSTRACT:
Dihydroisoindole compounds of formula (I), wherein the substituents are as defined herein, are disclosed as being useful as endothelin receptor antagonists. The compounds are applied in the treatment of cardiovascular and renal diseases. ##STR1##
REFERENCES:
patent: 2521416 (1950-09-01), Schmerling
patent: 3051707 (1962-08-01), Biel
patent: 3084167 (1963-04-01), Rice et al.
patent: 3428650 (1969-02-01), Houlihan
patent: 3466297 (1969-09-01), Sulkowski et al.
patent: 4163788 (1979-08-01), Carney
patent: 5073566 (1991-12-01), Lifer et al.
patent: 5312936 (1994-05-01), Lifer et al.
patent: 5563278 (1996-10-01), Lifer et al.
Elliott, et al., "1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists", Journal of Medicinal Chemistry, 37(11), pp. 1553-1557 (1994).
Elliott John Duncan
Franz Robert Gene
Gao Aiming
Lago M. Amparo
Hall Linda E.
Kinzig Charles M.
McKane Joseph K.
SmithKline Beecham Corporation
Venetianer Stephen A.
LandOfFree
Endothelin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Endothelin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endothelin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-879160